Wayne Winegarden
Blog
Read about a last minute Biden administration plan the Trump administration should undo
CMS’ Drug Price Controls Have Expanded to the Next 15 Medicare Part D Drugs
For every complex problem there is an answer that is clear, simple, and wrong. H.L. Mencken Back in 2022, the Biden Administration reasoned that drug costs are too high and devised a clear and simple answer: incorporate a Maximum Fair Price (MFP) provision into the Inflation Reduction Act of 2022 ...
Biosimilars
The Biosimilar Promise
Reforms Can Improve Competition and Generate More Savings
Reforms Can Improve Competition and Generate More Savings By Wayne Winegarden | January 7, 2025 READ PDF Executive Summary Reforms that will strengthen the biosimilar market and expand savings opportunities include: Reforming (ideally repealing) the Inflation Reduction Act’s price control measures. Improving the incentives underlying the current buy-and-bill system to ...
Blog
Grants Pass and Prop 36 Will Help Policymakers Control California’s Homeless Crisis
Between 2007 and 2014, homelessness declined faster in California than the rest of the country – an 18 percent total decline in California compared to a 9 percent total decline in the rest of the country. And then something happened in 2014. While the number of homeless in California began ...
Biosimilars
The Biosimilar Promise
Despite Achievements, Barriers That Discourage Biosimilar Use Remain
Despite Achievements, Barriers That Discourage Biosimilar Use Remain By Wayne Winegarden | December 2, 2024 READ PDF Executive Summary The Inflation Reduction Act’s price controls discourage biosimilar development. Payment system inefficiencies, such as the buy-and-bill payment system and rebate walls, disincentivize the use of lower cost biosimilars. Despite the savings ...
Biosimilars
The Biosimilar Promise
Low-Cost Biosimilars Are Saving Billions, Potential Savings Are Even Greater
Low-Cost Biosimilars Are Saving Billions, Potential Savings Are Even Greater By Wayne Winegarden | October 28, 2024 READ PDF Executive Summary Since 2019, biosimilars have obtained a majority share of most markets where they compete. The combination of lower prices (both biosimilar and originator) and rising market share could ...
Commentary
Learn more about how price controls are driving physician shortages
Price Controls Are Harming Doctors
Whether its pharmaceuticals or health insurance, Vice President Kamala Harris appears to have only one healthcare policy – impose price controls. The untenable financial position of many doctors and private doctor practices due to tightening Medicare reimbursement rates exemplifies the folly of her preferred approach. As I document in a recent ...
Blog
Learn how drug price controls hurt patients, innovation
Senator Sanders’ Price Controls Will Harm Patients
In a patently politicized press release, Senator Bernie Sanders (I-VT) who is Chairman of the Senate Health, Education, Labor, and Pensions (HELP) Committee, claims that the U.S. price of Ozempic is too high. As evidence, he cites generic companies that claim they can sell Ozempic for less than $100 a ...
Commentary
Learn why drug price controls don't work
The Expected Consequences Of Price Controls
The intended consequence of the policy is to reduce overall spending on drugs, but all regulations have unintended consequences, too. While these consequences may be unintended, they need not be unexpected. In the case of the IRA, these unintended impacts now threaten to undermine the entire purpose of the policy. ...
Blog
Read the latest on California's outmigration problem
Don’t Forget About Migration’s Long-term Implications
This exodus reflects the migrant’s view that California no longer offers a competitive lifestyle, and the state provides residents with inadequate economic opportunities. But the exodus from the state is not simply a statement on the Golden State’s current maladies. When people migrate, they take their income and economic activity ...
Business & Economics
NEW BRIEF: CalPERS’ Political Agenda Puts Taxpayers and Retirees at Risk with Low Returns, Higher Unfunded Liabilities
SACRAMENTO – CalPERS – which adheres to a politicized Environmental, Social, and Governance (ESG) agenda – is generating lower returns in its investment strategies compared to a more typical investment strategy, finds a new brief released today by the Pacific Research Institute, a non-partisan California-based free market think tank. CalPERS ...
Read about a last minute Biden administration plan the Trump administration should undo
CMS’ Drug Price Controls Have Expanded to the Next 15 Medicare Part D Drugs
For every complex problem there is an answer that is clear, simple, and wrong. H.L. Mencken Back in 2022, the Biden Administration reasoned that drug costs are too high and devised a clear and simple answer: incorporate a Maximum Fair Price (MFP) provision into the Inflation Reduction Act of 2022 ...
The Biosimilar Promise
Reforms Can Improve Competition and Generate More Savings
Reforms Can Improve Competition and Generate More Savings By Wayne Winegarden | January 7, 2025 READ PDF Executive Summary Reforms that will strengthen the biosimilar market and expand savings opportunities include: Reforming (ideally repealing) the Inflation Reduction Act’s price control measures. Improving the incentives underlying the current buy-and-bill system to ...
Grants Pass and Prop 36 Will Help Policymakers Control California’s Homeless Crisis
Between 2007 and 2014, homelessness declined faster in California than the rest of the country – an 18 percent total decline in California compared to a 9 percent total decline in the rest of the country. And then something happened in 2014. While the number of homeless in California began ...
The Biosimilar Promise
Despite Achievements, Barriers That Discourage Biosimilar Use Remain
Despite Achievements, Barriers That Discourage Biosimilar Use Remain By Wayne Winegarden | December 2, 2024 READ PDF Executive Summary The Inflation Reduction Act’s price controls discourage biosimilar development. Payment system inefficiencies, such as the buy-and-bill payment system and rebate walls, disincentivize the use of lower cost biosimilars. Despite the savings ...
The Biosimilar Promise
Low-Cost Biosimilars Are Saving Billions, Potential Savings Are Even Greater
Low-Cost Biosimilars Are Saving Billions, Potential Savings Are Even Greater By Wayne Winegarden | October 28, 2024 READ PDF Executive Summary Since 2019, biosimilars have obtained a majority share of most markets where they compete. The combination of lower prices (both biosimilar and originator) and rising market share could ...
Learn more about how price controls are driving physician shortages
Price Controls Are Harming Doctors
Whether its pharmaceuticals or health insurance, Vice President Kamala Harris appears to have only one healthcare policy – impose price controls. The untenable financial position of many doctors and private doctor practices due to tightening Medicare reimbursement rates exemplifies the folly of her preferred approach. As I document in a recent ...
Learn how drug price controls hurt patients, innovation
Senator Sanders’ Price Controls Will Harm Patients
In a patently politicized press release, Senator Bernie Sanders (I-VT) who is Chairman of the Senate Health, Education, Labor, and Pensions (HELP) Committee, claims that the U.S. price of Ozempic is too high. As evidence, he cites generic companies that claim they can sell Ozempic for less than $100 a ...
Learn why drug price controls don't work
The Expected Consequences Of Price Controls
The intended consequence of the policy is to reduce overall spending on drugs, but all regulations have unintended consequences, too. While these consequences may be unintended, they need not be unexpected. In the case of the IRA, these unintended impacts now threaten to undermine the entire purpose of the policy. ...
Read the latest on California's outmigration problem
Don’t Forget About Migration’s Long-term Implications
This exodus reflects the migrant’s view that California no longer offers a competitive lifestyle, and the state provides residents with inadequate economic opportunities. But the exodus from the state is not simply a statement on the Golden State’s current maladies. When people migrate, they take their income and economic activity ...
NEW BRIEF: CalPERS’ Political Agenda Puts Taxpayers and Retirees at Risk with Low Returns, Higher Unfunded Liabilities
SACRAMENTO – CalPERS – which adheres to a politicized Environmental, Social, and Governance (ESG) agenda – is generating lower returns in its investment strategies compared to a more typical investment strategy, finds a new brief released today by the Pacific Research Institute, a non-partisan California-based free market think tank. CalPERS ...
